Vaxxinity Announces First Parkinson’s Disease Patient Dosed in Part B of Phase 1 Clinical Trial of UB-312
January 12, 2022 09:21 ET
|
Vaxxinity, Inc.
DALLAS, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced that the first...
Vaxxinity Awarded Grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to Support UB-312 Vaccine Study
January 10, 2022 07:00 ET
|
Vaxxinity, Inc.
DALLAS, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (NASDAQ: VAXX), a clinical-stage biotech company pioneering a new class of immunotherapeutic vaccines to treat and prevent chronic...
Vaxxinity Appoints Jason Pesile as SVP, Finance & Accounting, and George Hornig to Board of Directors
January 04, 2022 07:00 ET
|
Vaxxinity, Inc.
DALLAS, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced the appointment of...
Vaxxinity Reports Third Quarter 2021 Financial Results and Provides Corporate Updates
December 23, 2021 16:45 ET
|
Vaxxinity, Inc.
DALLAS, Dec. 23, 2021 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported financial results for...
Vaxxinity Announces Closing of IPO and Partial Exercise of Underwriters’ Option to Purchase Additional Shares
November 18, 2021 16:05 ET
|
Vaxxinity, Inc.
DALLAS, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (“Vaxxinity”), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced the closing of its...
Vaxxinity Announces Pricing of Initial Public Offering
November 11, 2021 06:30 ET
|
Vaxxinity, Inc.
DALLAS, Texas, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (“Vaxxinity”), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced the pricing of...